Survival rate and outcomes of reverse total shoulder arthroplasty with a minimum ten-year follow-up using a trabecular metal implant

采用小梁金属植入物进行反向全肩关节置换术,至少随访十年,评估其生存率和疗效

阅读:1

Abstract

AIMS: There are few reports of outcomes after reverse total shoulder arthroplasty (RTSA) with over ten years of follow-up. Further, there is a lack of reports on RTSA with trabecular metal (TM) implants with ten-year follow-up. We aim to assess the ten-year survival and minimum ten-year outcomes of TM-RTSA. METHODS: All RTSA procedures were performed between October 2007 and July 2013 in a single institution. A consecutive series of 206 RTSAs in 194 patients were included in the Kaplan-Meier survival analysis using revision or removal for any reason as the endpoint. We also investigated the clinical and radiological outcomes at a minimum follow-up of ten years. RESULTS: Out of 206 RTSAs, there were a total of 13 failures. The median time from surgery was 1.6 years (IQR 0.08 to 7.5). The five-year implant survival rate was 94.7% (95% CI 89.9 to 97.2; 102 RTSAs at risk), and the ten-year rate was 90.5% (95% CI 82.9 to 94.8; 62 RTSAs at risk). Minimum ten-year outcomes were available for 60 RTSAs, including 57 with ASES scores and 40 RTSAs with radiographs with a mean follow-up period of 11.3 years. The ASES score was a median pain score of 50 (IQR 45 to 50) and a median functional score of 36.7 (IQR 23.3 to 41.7) on the ipsilateral side. In radiological analyses for 40 RTSAs, scapular notching was observed in 31 RTSAs (77.5%) and classified as grade III or IV, as described by Sirveaux et al, in five RTSAs (12.5%). Glenoid radiolucency was observed in 11 RTSAs (27.5%) and loosening in three RTSAs (7.5%). CONCLUSION: TM RTSA demonstrated a high ten-year survival rate of 90.5%. Although radiological findings increased over time, clinical outcomes remained favourable.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。